Cough News and Research

RSS

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

New cough suppressant from cocoa

People suffering from persistent cough may soon have a remedy that is derived from cocoa. At present researchers are carrying out the final stages of clinical trials of a drug that contains theobromine, an ingredient found in chocolate and cocoa. The drug could be in the market in another two years.

22 Dec 2010

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

SEEK, a leading UK privately-owned drug-discovery group, is pleased to announce the establishment of a new joint venture entity with Pernix Therapeutics Holdings, an integrated specialty pharmaceutical company focused primarily on the United States pediatric market.

20 Dec 2010

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.

19 Dec 2010

Rite Aid third quarter net loss decreases to $79.1 million

Rite Aid Corporation today reported financial results for its third fiscal quarter ended November 27, 2010.

16 Dec 2010

Accidental ingestion of Tessalon could be dangerous for young children, FDA warns

The U.S. Food and Drug Administration is warning that accidental ingestion of Tessalon (benzonatate) by children younger than 10 years can result in serious side effects or death.

15 Dec 2010

Pruritic nodules and aluminium allergy arise after vaccinations or treatments for allergies

Allergic contact dermatitis from aluminium has previously been considered very unusual. However, there are now reports of pruritic nodules and aluminium allergy arising after vaccinations or treatments for allergies.

14 Dec 2010

New theory explains spread of infectious diseases

New research using human-networking theory may give a clearer picture of just how, exactly, infectious diseases such as the common cold, influenza, whooping cough and SARS can spread through a closed group of people, and even through populations at large.

14 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.

8 Dec 2010

Lung transplant saves economist from near-lethal bout of swine flu

According to the critical care experts at The Johns Hopkins Hospital who treated him, Allen Bagents, 24, of Arlington, Va., is the least likely person anyone ever expects to get sick, let alone suffer a six-week, potentially fatal bout with the swine flu, better known as H1N1 influenza.

8 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.

7 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen today announced that it will present data from several key Nplate (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.

2 Dec 2010

Whooping cough on the move

The Sequoyah County has seen an increase of whooping cough cases this year while the state of Oklahoma has seen a decrease in cases according to health officials. Health officials in DuPage County also say there has been increase in whooping cough cases in recent weeks.

2 Dec 2010

Study finds inconsistency in OTC medications for children

Instructions on boxes and bottles of over-the-counter (OTC) medicines for children in the United States are confusing and hard for parents to understand and follow, according to a study in the December 1 issue of JAMA.

2 Dec 2010

Cough News and Research

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

FDA approves Novartis' Amturnide for treatment of high blood pressure

New cough suppressant from cocoa

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

Rite Aid third quarter net loss decreases to $79.1 million

Accidental ingestion of Tessalon could be dangerous for young children, FDA warns

Pruritic nodules and aluminium allergy arise after vaccinations or treatments for allergies

New theory explains spread of infectious diseases

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Lung transplant saves economist from near-lethal bout of swine flu

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Whooping cough on the move

Study finds inconsistency in OTC medications for children

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News